MORF
NASDAQMorphic Holding Inc.
Latest news
25 items- PROmega Funds Closes Oversubscribed $647 Million Fund VIII to Invest in Transformative Life Science CompaniesOmega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. Since its inception in 2004, Omega Funds has raised $2.5 billion to invest in exceptional entrepreneurs developing
- SECSEC Form 15-12G filed by Morphic Holding Inc.15-12G - Morphic Holding, Inc. (0001679363) (Filer)
- INSIDERDirector Edwards Martin returned 2,376 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Morphic Holding, Inc. (0001679363) (Issuer)
- INSIDERDirector Slattery Joseph P returned 9,066 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Morphic Holding, Inc. (0001679363) (Issuer)
- INSIDERDirector Nashat Amir closing all direct ownership in the company (SEC Form 4)4 - Morphic Holding, Inc. (0001679363) (Issuer)
- INSIDERDirector Springer Timothy A closing all direct ownership in the company (SEC Form 4)4 - Morphic Holding, Inc. (0001679363) (Issuer)
- INSIDERPresident and CEO Tipirneni Praveen P. closing all direct ownership in the company (SEC Form 4)4 - Morphic Holding, Inc. (0001679363) (Issuer)
- INSIDERSEC Form 4 filed by Director Gray Susannah4 - Morphic Holding, Inc. (0001679363) (Issuer)
- INSIDERDirector Christensen Gustav returned 100,517 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Morphic Holding, Inc. (0001679363) (Issuer)
- INSIDERSEC Form 4 filed by Director Bischofberger Norbert W4 - Morphic Holding, Inc. (0001679363) (Issuer)
- INSIDERSEC Form 4 filed by CMO Cooper Simon Peter4 - Morphic Holding, Inc. (0001679363) (Issuer)
- INSIDERGeneral Counsel and Secretary Devaul William returned 19,587 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Morphic Holding, Inc. (0001679363) (Issuer)
- INSIDERPRESIDENT Rogers Bruce returned 149,883 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Morphic Holding, Inc. (0001679363) (Issuer)
- INSIDERCFO and COO Schegerin Marc returned 37,907 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Morphic Holding, Inc. (0001679363) (Issuer)
- INSIDERSVP Finance and CAO Farrell Robert E Jr returned 12,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Morphic Holding, Inc. (0001679363) (Issuer)
- SECSEC Form S-8 POS filed by Morphic Holding Inc.S-8 POS - Morphic Holding, Inc. (0001679363) (Filer)
- SECSEC Form S-8 POS filed by Morphic Holding Inc.S-8 POS - Morphic Holding, Inc. (0001679363) (Filer)
- SECSEC Form S-8 POS filed by Morphic Holding Inc.S-8 POS - Morphic Holding, Inc. (0001679363) (Filer)
- SECSEC Form S-8 POS filed by Morphic Holding Inc.S-8 POS - Morphic Holding, Inc. (0001679363) (Filer)
- SECSEC Form S-8 POS filed by Morphic Holding Inc.S-8 POS - Morphic Holding, Inc. (0001679363) (Filer)
- SECSEC Form S-8 POS filed by Morphic Holding Inc.S-8 POS - Morphic Holding, Inc. (0001679363) (Filer)
- SECSEC Form POSASR filed by Morphic Holding Inc.POSASR - Morphic Holding, Inc. (0001679363) (Filer)
- SECSEC Form POSASR filed by Morphic Holding Inc.POSASR - Morphic Holding, Inc. (0001679363) (Filer)
- SECSEC Form 8-K filed by Morphic Holding Inc.8-K - Morphic Holding, Inc. (0001679363) (Filer)
- SECSEC Form 25-NSE filed by Morphic Holding Inc.25-NSE - Morphic Holding, Inc. (0001679363) (Subject)
MORF FAQ
7 questionsWhat does Morphic Holding Inc. do?
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4Ã7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and MORF-720 and MORF-627, which is in the preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avÃ1 for the treatment of fibrotic...Where does MORF stock trade?
Morphic Holding Inc. (MORF) is listed on NASDAQ.What sector and industry is MORF in?
Morphic Holding Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Morphic Holding Inc. go public?
Morphic Holding Inc. (MORF) completed its IPO in 2019.What are analysts saying about MORF?
Morphic Holding Inc. has had 8 recent analyst actions on file. The most recent action was from Citigroup: Buy with a $4600.00 price target on 2023-12-08. Recent price targets range from $3300.00 to $4600.00.What companies are similar to MORF?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare MORF side-by-side with any of them on Quantisnow.How can I track MORF on Quantisnow?
Quantisnow aggregates Morphic Holding Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MORF to receive live email and push alerts on every new disclosure.